MaxCyte Inc. (MXCT)
NASDAQ: MXCTHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
MXCT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $141.45M
- EPS (TTM)
- -$0.26
- Dividend yield
- None
- 52-week range
- 0.643 – 1.80
- Day range
- 1.27 – 1.42
- Volume / Avg
- 1.11M / 1.04M
- Beta
- —
- Shares outstanding
- 103.25M
52-week range
MXCT stock today
Shares of MaxCyte (MXCT) finished higher on Nov 20 at $1.37, a gain of 7.03% or $0.09 per share, versus the S&P 500's 3.70% decline. At this level, MXCT sits in the middle of its 52-week range of $0.643 to $1.80: 23.9% below the high, set on Nov 28, 2025 and 113.1% above the low. MXCT is down 11.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 18.0%.
MaxCyte has posted a net loss over the last twelve months (EPS of -$0.26), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About MaxCyte
Company profileMaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols.
- Sector
- Health Care
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- CEO
- Mr. Maher Masoud
- Headquarters
- Rockville, MD
- Employees
- 91
- IPO year
- 2021
- Website
- maxcyte.com
Financial highlights
Full financialsIn fiscal 2025, MaxCyte generated $33.0 million in revenue, down 14.5% from fiscal 2024, its first annual decline since 2024. MaxCyte reported a net loss of $44.6 million, compared with a loss of $41.1 million a year earlier. Gross margin was 81.2% (down from 81.6%) and operating margin -157.1%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $33.03M | $38.63M | $41.29M | $44.26M | $33.89M |
| Growth | -14.50% | -6.44% | -6.72% | +30.59% | +29.52% |
| Net income | $-44.63M | $-41.05M | $-37.92M | $-23.57M | $-19.08M |
| EPS (diluted) | $-0.42 | $-0.39 | $-0.37 | $-0.23 | $-0.21 |
Analyst forecast
ForecastConsensus (6 analysts)
strong_buy
Avg. price target
$4.11+200.00%
- Strong buy 0
- Buy 5
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 10, 2026
- EPS actual vs est.
- $-0.05 vs $-0.08
- Surprise
- +37.50%
MXCT news
All MXCT news- MaxCyte (MXCT) Q3 2026 Earnings Call TranscriptNasdaq
- MaxCyte To Acquire AkronNasdaqMXCT, MKC.V
- MaxCyte, Inc. Q3 Loss DeclinesNasdaqMXCT, MKC.V
- MaxCyte Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Total Revenue GuidanceGlobeNewswire
- MaxCyte to Acquire Akron Bio, Expanding its Offerings Across Cell Therapy Manufacturing and Expecting to Nearly Double Revenue BaseGlobeNewswire
- MaxCyte to Participate in Three Upcoming Investor ConferencesGlobeNewswire
- MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue GuidanceGlobeNewswire
- Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue EstimatesNasdaqKYMR, MXCT
MaxCyte peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ONMDOneMedNet Corp Class A | 4.70 | +4.21% | $29.15M | vs MXCT |
| BIAFbioAffinity Technologies Inc. | 1.65 | -10.81% | $3.00M | vs MXCT |
| ISPCiSpecimen Inc. | 0.4563 | -13.58% | $2.64M | vs MXCT |
| NRCNRC Health | 25.16 | +0.68% | $533.93M | vs MXCT |
| OABIOmniAb Inc. | 4.66 | -7.36% | $679.71M | vs MXCT |
| ABSIAbsci Corporation | 7.51 | -7.97% | $1.30B | vs MXCT |
| ICLRICON plc | 186.71 | -1.92% | $13.99B | vs MXCT |
| CRLCharles River Laboratories International Inc. | 314.32 | -4.15% | $15.06B | vs MXCT |
Indexes, lists and sector
MaxCyte stock FAQ
What is MaxCyte's stock price today?
MXCT last traded at $1.37 as of Nov 20, 4:00 PM EST, up 7.03% on the day. Prices are delayed at least 15 minutes.
Who is MaxCyte's CEO?
Mr. Maher Masoud is the chief executive officer of MaxCyte Inc., which has about 91 employees.
What is the MXCT 52-week high?
The 52-week high for MXCT is $1.80 and the 52-week low is $0.643. The stock is currently 23.9% below its high.